Electromed (NYSE:ELMD) Downgraded by StockNews.com

Electromed (NYSE:ELMD) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Separately, TheStreet raised Electromed from a “c+” rating to a “b-” rating in a report on Wednesday, February 21st.

Electromed Trading Down 4.4 %

Shares of Electromed stock opened at $15.99 on Friday. The company’s fifty day simple moving average is $15.64 and its 200-day simple moving average is $12.26. The company has a market cap of $137.67 million, a price-to-earnings ratio of 35.53 and a beta of 0.43. Electromed has a 1 year low of $8.80 and a 1 year high of $17.85.

Electromed (NYSE:ELMD) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $0.19 earnings per share (EPS) for the quarter. The business had revenue of $13.69 million for the quarter. Electromed had a net margin of 7.62% and a return on equity of 10.32%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Electromed stock. Hunter Associates Investment Management LLC increased its stake in shares of Electromed, Inc. (NYSE:ELMD) by 6.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,500 shares of the company’s stock after buying an additional 5,000 shares during the period. Hunter Associates Investment Management LLC owned 0.94% of Electromed worth $837,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 40.82% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function.